New Research Suggests Ozempic and Similar Drugs May Affect Alcohol Cravings
- biobondlabs
- May 8
- 6 min read
Important: This article is intended for educational and informational purposes only. It is not medical advice and should not be interpreted as a recommendation to use Ozempic, Wegovy, Mounjaro, Zepbound, or any GLP-1 medication to treat alcohol use disorder or substance addiction. Research in this area is still emerging, and these medications are not FDA-approved for the treatment of alcohol use disorder.
New Research Suggests Ozempic and Similar Drugs May Affect Alcohol Cravings
For years, medications like Ozempic and Wegovy have been discussed primarily through the lens of weight loss and diabetes treatment. Now, researchers are studying another possible effect that many patients have already been talking about online for months: reduced interest in alcohol.
A newly published randomized controlled trial in The Lancet is adding scientific weight to those reports, finding that semaglutide, the active ingredient in Ozempic and Wegovy, was associated with significant reductions in heavy drinking among adults with alcohol use disorder and obesity. The findings are drawing attention not only because of what they showed, but because they may point toward a broader connection between GLP-1 medications, reward pathways, and addictive behavior.
What the New Study Found
The study, published May 2, 2026 in The Lancet, followed 108 adults diagnosed with both alcohol use disorder and obesity. Participants were randomly assigned to receive either semaglutide or placebo over a 26-week period in a double-blind, placebo-controlled trial design, which is considered one of the strongest forms of clinical research.
Researchers found that participants receiving semaglutide experienced a significantly greater reduction in heavy drinking days compared with the placebo group. According to the published data, heavy drinking days fell by roughly 41% in the semaglutide group compared with approximately 26% in the placebo group. The study also reported improvements across several alcohol-related secondary outcomes.
Importantly, participants in both groups also received behavioral therapy during the trial, meaning researchers were not evaluating semaglutide as a standalone addiction treatment.
Why Researchers Are Studying Ozempic Alcohol Cravings
Scientists have been investigating the relationship between GLP-1 signaling and the brain’s reward system for several years. GLP-1 receptors are found not only in areas involved in blood sugar regulation and appetite, but also in regions associated with reward, motivation, impulse control, and reinforcement behavior.
That overlap is one reason researchers believe these medications may influence cravings extending beyond food alone. Earlier animal studies had already suggested that GLP-1 receptor agonists could reduce alcohol-seeking behavior and lower alcohol consumption under experimental conditions.
At the same time, patient forums and social media platforms became flooded with anecdotal reports from people claiming they suddenly lost interest in alcohol after starting medications like Ozempic, Wegovy, Mounjaro, or Zepbound. Until recently, however, strong human clinical evidence remained limited.
Interest in “Ozempic alcohol cravings” has surged online as patients report unexpected changes in drinking behavior while using GLP-1 medications.
Could Other GLP-1 Drugs Have Similar Effects?
Possibly, although researchers do not yet know how broadly these findings apply across the entire category of GLP-1 and incretin-based medications.
The strongest human evidence currently centers on semaglutide because that was the medication evaluated in the newly published Lancet trial. However, scientists are increasingly interested in whether the observed effects may relate more generally to GLP-1 receptor activity itself rather than to one individual drug.
That has expanded attention toward medications including Wegovy, Ozempic, Mounjaro, Zepbound, and liraglutide-based therapies. Tirzepatide-containing medications such as Mounjaro and Zepbound are particularly interesting because they target both GLP-1 and GIP receptors, potentially influencing reward pathways differently from semaglutide alone.
Researchers caution against assuming all GLP-1 medications will produce identical effects. The mechanisms remain incompletely understood, and significantly larger studies are still needed before broader conclusions can be made.
What the Study Does NOT Prove
Despite the attention surrounding the findings, experts caution that the study should not be interpreted as proof that Ozempic or similar medications “treat alcoholism.”
Several important limitations remain. The study population was relatively small, and participants also had obesity, meaning the findings may not apply broadly to all patients with alcohol use disorder. Behavioral therapy was included alongside treatment, long-term outcomes remain unclear, and the medications are not FDA-approved for alcohol use disorder.
Researchers also do not fully understand whether the observed changes are driven primarily by appetite regulation, reward signaling, reduced impulsivity, altered dopamine pathways, or some combination of multiple neurological effects. That distinction matters because it affects how broadly these findings could eventually apply.
Why the Findings Are Getting So Much Attention
Alcohol use disorder affects millions of people in the United States, yet treatment options remain limited and often underutilized. Existing FDA-approved medications for alcohol use disorder can help some patients, but treatment adherence and effectiveness vary considerably.
That is one reason addiction researchers are paying close attention to medications that may influence cravings and reinforcement pathways in new ways. The emergence of GLP-1 drugs as a possible area of addiction research has generated unusual interest across multiple medical fields at once, including obesity medicine, psychiatry, endocrinology, and addiction treatment.
At the same time, experts caution that public enthusiasm is moving faster than the science itself. Multiple additional trials are already underway to determine whether these findings can be replicated, how durable the effects may be over time, and whether similar patterns emerge with other GLP-1 medications.
What Consumers Should Take Away From This
The new Lancet study does not mean Ozempic, Wegovy, Mounjaro, or Zepbound should currently be viewed as established treatments for alcohol addiction. What it does mean is that researchers are now taking a phenomenon once dismissed as anecdotal much more seriously.
The findings suggest there may be a meaningful biological connection between GLP-1 signaling, cravings, and addictive behaviors that deserves further investigation. Whether that eventually changes addiction treatment in a major way remains unknown.
For now, the research is moving from internet speculation into legitimate clinical science.
Disclaimer
This content is for educational and informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any condition. Always consult a licensed healthcare provider regarding medications, alcohol use disorder, substance use disorder, or treatment decisions. Individual responses may vary.
BioBond Labs™ products are intended for laboratory research use only and are not for human or veterinary consumption.
References
Grunebaum MF, O’Malley SS, Gueorguieva R, et al. Semaglutide treatment for alcohol use disorder in adults with obesity: a randomized clinical trial. Lancet. Published online May 2, 2026.
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756.
Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(suppl 1):5-21.
Vallof D, Ulenius L, Egecioglu E, Engel JA, Jerlhag E. Central administration of glucagon-like peptide-1 analogues decreases alcohol-mediated behaviors in rodents. Addict Biol. 2016;21(2):422-437.
Søndergaard HP, Knudsen GM, Wortwein G, et al. Glucagon-like peptide-1 receptor agonists and alcohol-related behaviors: preclinical evidence and emerging mechanisms. Front Neurosci. 2023;17:1182445.
National Institute on Alcohol Abuse and Alcoholism. Alcohol Use Disorder (AUD) in the United States: Age Groups and Demographic Characteristics. Updated 2025.
U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. Revised 2025.
U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. Revised 2025.
U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information. Revised 2025.
U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. Revised 2025.
ClinicalTrials.gov. Semaglutide treatment for alcohol use disorder clinical trial listings. U.S. National Library of Medicine. Accessed May 2026.
Lee MR, Leggio L. Combined pharmacotherapies for alcohol use disorder: current evidence and future directions. Alcohol Res. 2022;42(1):09.
Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760-773.
Jerlhag E. Gut-brain signaling and compulsive behaviors: emerging implications for GLP-1 receptor agonists. Neuropharmacology. 2024;231:109540.
O’Malley SS, Rounsaville BJ, Farren C, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of three randomized trials. Arch Intern Med. 2003;163(14):1695-1704.
Comments